Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.39 |
| ▸ | MMP9 | P14780 | 10/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 7/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869411 | 1.00 | MMP1 (0.39) | MMP1MMP9NTSR1MMP3ACE | |
| SCHEMBL5869421 | 1.00 | MMP1 (0.39) | MMP1MMP9NTSR1MMP3ACE | |
| SCHEMBL7426808 | 0.86 | MMP1 (0.46) | MMP1MMP9NTSR1MMP3ACE | |
| SCHEMBL5870089 | 0.83 | ANPEP (0.38) | MMP1MMP9MMP3 | |
| SCHEMBL5870321 | 0.83 | ANPEP (0.38) | MMP1MMP9MMP3 | |
| SCHEMBL5870317 | 0.83 | ANPEP (0.38) | MMP1MMP9MMP3 | |
| SCHEMBL5870188 | 0.82 | MMP1 (0.48) | MMP1MMP9NTSR1MMP3PSEN1 | |
| SCHEMBL5869703 | 0.82 | MMP1 (0.48) | MMP1MMP9NTSR1MMP3PSEN1 | |
| SCHEMBL5870191 | 0.82 | MMP1 (0.48) | MMP1MMP9NTSR1MMP3PSEN1 | |
| SCHEMBL7429682 | 0.80 | NTSR1 (0.37) | MMP1MMP9NTSR1MMP3PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | MMP1 1393/4885MMP9 1346/4885NTSR1 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.